Financial Performance - Revenues for the nine months ended September 30, 2023, were $1,087,000, a 114% increase compared to $506,000 for the same period in 2022[21]. - Gross loss decreased to $561,000 for the nine months ended September 30, 2023, compared to a gross loss of $773,000 in the same period of 2022, reflecting a 27.4% improvement[21]. - Operating loss for the nine months ended September 30, 2023, was $8,770,000, compared to $7,675,000 for the same period in 2022, indicating a 14.3% increase in losses[21]. - Net loss for the nine months ended September 30, 2023, was $8,104,000, slightly higher than the net loss of $7,804,000 in the same period of 2022, representing a 3.8% increase[21]. - Revenues for the three months ended September 30, 2023, were $110,000, a decrease of $24,000, or 18%, from $134,000 for the same period in 2022[104]. - Cost of revenues increased by 29% to $1,648,000 for the nine months ended September 30, 2023, up from $1,279,000 in 2022[81]. - Sales and marketing expenses increased by 42% to $877,000 for the nine months ended September 30, 2023, up from $617,000 in 2022[90]. - General and administrative expenses for the nine months ended September 30, 2023, were $3,225,000, a decrease of $37,000, or 1%, compared to $3,262,000 for the same period in 2022[94]. Assets and Cash Flow - Total assets increased to $24,556,000 as of September 30, 2023, up from $16,895,000 at the end of 2022, representing a 45.5% growth[15]. - Cash and cash equivalents rose to $15,938,000 as of September 30, 2023, compared to $10,099,000 at the end of 2022, marking a 57.5% increase[15]. - The company accumulated a deficit of approximately $32.9 million as of September 30, 2023, primarily funded by shareholders[40]. - Cash used in operating activities for the nine months ended September 30, 2023, was $7,338,000, compared to $4,107,000 for the same period in 2022, representing an increase of $3,231,000, or 78.7%[96][98]. - Cash provided by financing activities during the nine months ended September 30, 2023, was $13,835,000, consisting of cash proceeds from issuance of shares and warrants[102]. - The company's cash and short-term deposit balance as of September 30, 2023, was $19.5 million, indicating a need for substantial additional funding to support operations and product development[153]. Research and Development - Research and development expenses for the nine months ended September 30, 2023, were $4,107,000, up from $3,023,000 in the same period of 2022, indicating a 36% increase[21]. - The company expects to continue incurring significant research and development costs, necessitating additional funding to sustain operations until profitability is achieved[40]. - The company expects research and development expenses to continue increasing as it expands its focus on I4.0 domain activities[88]. - Research and development expenses for the three months ended September 30, 2023, were $1,354,000, an increase of $306,000, or 29%, compared to $1,048,000 for the same period in 2022[111]. Shareholder and Stock Information - The company issued 3,294,000 shares and warrants during the nine months ended September 30, 2023, contributing to additional paid-in capital of $13,818,000[24]. - Mr. Arkin beneficially owns approximately 55.62% of the Common Stock, which gives him significant control over corporate decisions[198]. - As of September 22, 2023, directors, executive officers, principal stockholders, and affiliated entities own approximately 84.56% of the outstanding voting securities, allowing them to exert substantial influence over company decisions[211]. - Future issuances of Common Stock or other securities may dilute the ownership interests of current stockholders, particularly in connection with capital raising activities and employee retention[210]. Risks and Challenges - The company has not achieved profitability in any full fiscal year since inception, raising concerns about its ability to sustain operations and growth[148]. - The company is reliant on third-party suppliers for most components, which could hinder its ability to meet product demand in a timely and cost-effective manner[163]. - The company faces significant risks from weakened global economic conditions, which could adversely affect its financial performance and operations[159]. - The ongoing effects of the COVID-19 pandemic remain unpredictable and could significantly impact future results and overall financial performance[162]. - The company may struggle to establish effective sales, marketing, and distribution capabilities, which are crucial for commercializing its products[149]. - The company anticipates competition from customers, which could adversely affect its market position and financial results[154]. - The company may not be able to manage its growth effectively, which could impair its business and operational capabilities[154]. - The company is subject to various regulatory risks, including compliance with anti-bribery and anti-corruption laws, which could lead to penalties and other adverse consequences[154]. - The company may face challenges in enforcing its patents, especially in foreign jurisdictions, which could limit its ability to protect its intellectual property[178]. Market and Economic Conditions - The impact of military conflicts, such as the ongoing situation between Russia and Ukraine, may adversely affect financial markets and the global economy[209]. - Sanctions imposed by the United States and other countries in response to geopolitical conflicts could exacerbate market instability[209]. - General market conditions and external factors beyond the company's control may influence its financial performance[209]. - The volatility of the stock market, particularly for life sciences companies, may not relate to the company's operating performance and could lead to litigation[205]. Compliance and Legal Issues - The company may be subject to product liability claims, which could divert management's attention and harm its business[187]. - Compliance with anti-bribery and anti-corruption laws is critical, as violations could lead to severe penalties and damage to the company's reputation[171]. - The company may struggle to protect its intellectual property rights, which could diminish the value of its proprietary technology and lead to increased legal expenses[181]. - Infringement claims from other parties could result in costly litigation and divert management resources, impacting overall business operations[182].

Financial Performance - Revenues for the six months ended June 30, 2023, were $977,000, a 163% increase compared to $372,000 for the same period in 2022[21]. - Revenues for the three months ended June 30, 2023, were $674,000, an increase of $304,000, or 82%, compared to $370,000 for the same period in 2022[100][101]. - Gross loss decreased to $350,000 for the six months ended June 30, 2023, compared to a gross loss of $477,000 for the same period in 2022, reflecting improved operational efficiency[21]. - Gross loss for the three months ended June 30, 2023, was $103,000, a decrease of $88,000, or 46%, compared to a gross loss of $191,000 for the same period in 2022[100][105]. - Operating loss for the six months ended June 30, 2023, was $5,898,000, compared to an operating loss of $5,350,000 for the same period in 2022[21]. - Operating loss for the three months ended June 30, 2023, was $3,119,000, an increase of $538,000 compared to an operating loss of $2,581,000 for the same period in 2022[100][115]. - Net loss for the six months ended June 30, 2023, was $5,562,000, slightly higher than the net loss of $5,560,000 for the same period in 2022[21]. Expenses - Research and development expenses rose to $2,753,000 for the six months ended June 30, 2023, up 39.2% from $1,975,000 in the same period of 2022[21]. - Research and development expenses for the three months ended June 30, 2023, were $1,355,000, an increase of $334,000, or 33%, compared to $1,021,000 for the same period in 2022[100][108]. - Sales and marketing expenses increased by 50% to $669,000 for the six months ended June 30, 2023, from $446,000 in 2022[86]. - Sales and marketing expenses for the three months ended June 30, 2023, were $493,000, an increase of $290,000, or 143%, compared to $203,000 for the same period in 2022[100][110]. - General and administrative expenses decreased by 13% to $2,126,000 for the six months ended June 30, 2023, compared to $2,452,000 in 2022[90]. - Total stock-based payment expenses for the six months ended June 30, 2023, amounted to $685,000, distributed across various expense categories[60]. Assets and Equity - Total assets increased to $26,409,000 as of June 30, 2023, up from $16,895,000 at the end of 2022, representing a 56.5% growth[15]. - Total shareholders' equity increased to $20,796,000 as of June 30, 2023, from $11,786,000 at the end of 2022, marking a 76.2% increase[18]. - Cash and cash equivalents decreased to $3,319,000 as of June 30, 2023, down from $10,099,000 at the end of 2022, indicating a cash outflow[15]. - The accumulated deficit as of June 30, 2023, was approximately $30.3 million, compared to $24.8 million as of December 31, 2022[122]. Funding and Capital - The company issued 3,294,000 shares and warrants, raising $13,887,000 in additional paid-in capital during the first half of 2023[24]. - The company raised $14 million through a private placement on March 16, 2023, selling 3,294,117 units at a price of $4.25 per unit[51]. - The company expects to incur significant research and development costs, necessitating additional funding to continue operations until profitability is achieved[39]. - The company expects to incur significant commercialization expenses related to product sales, marketing, manufacturing, and distribution[124]. Lease and Liabilities - As of June 30, 2023, the company had total lease liabilities of $571,000, with future lease payments totaling $622,000[50]. - The company has a weighted average remaining lease term of 0.9 years and a weighted average discount rate of 6% as of June 30, 2023[49]. - The company had 1,596,675 stock options outstanding at the end of the period, with a weighted average exercise price of $3.68[57]. Product and Technology - The company’s products utilize micro visualization technology for minimally invasive medical procedures, targeting various industries including aviation and energy[37]. - Remaining Performance Obligations (RPO) as of June 30, 2023, amounted to $2.9 million, expected to be recognized over the product's manufacturing term[64]. Cash Flow - Cash used in operating activities was $5,083,000 for the six months ended June 30, 2023, compared to $2,398,000 in 2022[93]. - Cash used in investing activities was $15,557,000 for the six months ended June 30, 2023, compared to cash provided of $1,458,000 in 2022[98]. - Cash used in operating activities for the three months ended June 30, 2023, was $2.6 million, consisting of a net loss of $2.9 million[116][118].

Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 333-188920 SCOUTCAM INC. (Exact name of registrant as specified in its charter) Nevada 47-4257143 (State or other jurisdiction of incorpor ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended: December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 333-188920 SCOUTCAM INC. (Exact name of registrant as specified in its charter) Washington, D.C. 20549 FORM 10-K (Mark One) Tel: +972 73 370-4691 Securities registered pursuant to Section 12(g) of the Act: None Nev ...